Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals

Authors

  • Bader Faiyaz Zuberi DUHS

Abstract

Treating hepatitis C has never been so convenient after the advent of Directly Acting Antivirals (DAA). Convenience is at both ends; for the doctors to prescribe and for patients to comply due to all oral therapy with few adverse effects. Many are already in market, these include, Sofosbuvir, Declastavir & Velpastavir while many others are in pipeline. The SVR success rates with
these newer drugs is approaching 99% and they are also showing improvement in fibrosis1,2. Cost of innovative brands of DAAs is very high. According to one study Quality-Adjusted Life Years (QALY) with innovator sofosbuvir for short therapy resulted in expense of $24,000 as compared to no treatment3 . Pakistan being a poor country with low per capita income, health and
innovator brand medicines are not in approach of average patient. With availability of generics there is up to 70%
reduction in cost of treatment and they come into the affordability range of most of the patients4-7
.

Downloads

Download data is not yet available.

Author Biography

Bader Faiyaz Zuberi, DUHS

Department of Medicine Professor

Downloads

Published

2017-08-29

How to Cite

Zuberi, B. F. (2017). Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals. Journal of the Dow University of Health Sciences (JDUHS), 11(2), 29–30. Retrieved from https://jduhs.com/index.php/jduhs/article/view/1381

Issue

Section

Editorial

Most read articles by the same author(s)